

Georgia Country Coordinating Mechanism

Oversight Committee

Meeting dedicated to the discussion of the HIV and TB dashboards for Period 6

November 25, 2015

David Ananiashvili – CCM, Chair of the Oversight Committee;

Nino Lortkipanidze – NCDCPH, PIU, GFATM TB Program Manager

Keti Stvilia - NCDCPH, PIU, GFATM HIV Program Manager

George Kuchukhidze – NCDC, PIU, TB M&E Officer

Alexander Asatiani - NCDCPH, PIU, GFATM HIV M&E Specialist

Nino Vakhania - NCDCPH, PIU, GFATM Programs Financial Manager

Natia Khonelidze – CCM Administrative Assistant

The meeting was dedicated to the discussion of any existing or potential challenges observed in GFATM funded programs implementation and discussion the data of HIV and TB dashboards for P6 (Quarter 3, July 1-September 30, 2015).

Alexander Asatiani –presented to the audience the financial, management and programmatic data of the HIV dashboard for P6. While speaking on fund disbursements Mr. Asatiani noted the funds during the reporting period were directly disbursed by the Global Fund to the PPM Agent; the funds disbursement cycle from PR to SR happened as planned. Mr. Asatiani noted that a slight variance between budget and actual expenditures (f2) has occurred due to currency exchange rate fluctuation. While discussing management indicators he noted that the vast majority of CPs and TBA are fulfilled (M1). Following the full implementation of Objective 1 all 12 SRs are identified and contracted (M3). The rapporteur underlined that there is an improvement in implementation of M5 - Budget and Procurement of health products, health equipment, medicines and pharmaceuticals, as for variances reflected in the dashboard it is due to currency exchange rate variance and the savings related to the tender procedures. Mr. Asatiani underlined that procedures related to procurement of methadone of 2016 stock are in ongoing state including discussions concerning the quota. Regarding the stock of 1 ml syringes, it was noted that to avoid anticipated stock out, 10% of the total IDA order was delivered by air shipment throughout reporting period. Remaining quantity will be delivered in the beginning of P7 (M6). Afterwards Mr. Asatiani focused on programmatic indicators and noted that some underachievement (86%) was observed in relation to P4 and P5 - Number of MARPs (IDUs, MSM and FSWs) covered with HIV testing and counselling (including provision of results).

The audience discussed possible reasons and ways for improvement.

David Ananiashvili – stated that it would be highly desirable to conduct a field visits to Zugdidi and Batumi to study the case on site and to establish a direct communication with the program beneficiaries.

Giorgi Kuchukhidze - presented to the audience the financial, management and programmatic data of TB dashboard for P6. No significant developments for reporting in terms of financial data were observed during the reporting period. The procurement of the 2nd line anti-TB drugs will occur in Q4. Mr. Kuchukhidze focused on the excessive quantity of Clofazimine and explained that the expiration date of the drug is March 2019 and the usage is expected to be increased. Thus it is expected to be duly utilized. He presented a slight underachievement in relations with following indicators stating that it is most probably relates to the actual (decreased) number of TB patients in the country:

Number of notified cases of all forms of TB - (i.e. bacteriologically confirmed +clinically diagnosed) (new and relapse) – 69%.

Number of bacteriologically confirmed TB cases in a specified period who subsequently were successfully treated (sum of WHO outcome categories "cured" plus "treatment completed") – 68%.

Number of TB patients enrolled on standardized 1st line treatment in the specified calendar year – 67%.

Laboratory-confirmed X/MDR-TB patients enrolled on second line anti-TB treatment in the specified calendar year – 82%.

David Ananiashvili – stated that the reasons for relatively low indicator related to the actual (decreased) number of TB patients in the country should be thoroughly studied. Thus conducting of a research by NCDCPH in close collaboration with NCTLD is of an utmost importance.

Giorgi Kuchukhidze – announced that the PR has undertaken preliminary analyses of the cash incentive scheme implementation and presented to the audience some results.

David Ananiashvili – highly emphasized the importance of this work and expressed a notion that the results of the study should be presented to the CCM members at one of the nearest CCM meetings. In addition, the implementation of the cash incentive scheme will be one of the topics of discussions during the meeting with staff of TB institutions during the planned field visit. He noted that proposed by PR at the previous meeting new dashboard reporting arrangements was agreed with OC and will be presented to the CCM members for final agreement at the next meeting. Finally, he announced that the OC will further analyze the dashboards data (which had been presented to the OC well in advance) and will present its recommendations to the CCM members at the 81-st CCM meeting scheduled for November 27.

David Ananiashvili

Chair of the Oversight Committee

Natia Khonelidze

Administrative Assistant to the CCM

Attachment: HIV and TB dashboards for Period 6